Cargando…

Time for tocilizumab in COVID-19?

Detalles Bibliográficos
Autores principales:	Butler, Ethan, Munch, Marie Warrer, Venkatesh, Balasubramanian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165681/ https://www.ncbi.nlm.nih.gov/pubmed/34057560 http://dx.doi.org/10.1007/s00134-021-06441-y

Ejemplares similares

Tocilizumab and COVID-19
por: Chaudhry, Dhruva, et al.
Publicado: (2020)

Tocilizumab in COVID-19: Is the Temptation Worthwhile?
por: Gupta, Sachin, et al.
Publicado: (2021)

Tocilizumab for Covid-19 — The Ongoing Search for Effective Therapies
por: Huang, Edmund, et al.
Publicado: (2020)

One year later: The case of tocilizumab in COVID-19
por: Campochiaro, Corrado, et al.
Publicado: (2022)

COVID-19 : encore une place pour le tocilizumab ?
por: Richier, Q., et al.
Publicado: (2021)

Tocilizumab and COVID-19: Timing of administration assessment
por: Richier, Q., et al.
Publicado: (2022)

Tocilizumab and COVID-19: Timing of Administration and Efficacy
por: Abidi, Emna, et al.
Publicado: (2022)

Heterogeneous treatment effects of dexamethasone 12 mg versus 6 mg in patients with COVID‐19 and severe hypoxaemia—Post hoc exploratory analyses of the COVID STEROID 2 trial
por: Granholm, Anders, et al.
Publicado: (2022)

How likely are COVID-19 interventions to benefit the sickest patients?
por: Perner, Anders, et al.
Publicado: (2020)

Tocilizumab in patients with COVID-19: which patient, time, and dose?
por: Hasanin, Ahmed, et al.
Publicado: (2021)

Tocilizumab in COVID-19 management: addressing time of starting treatment
por: Khiali, Sajad, et al.
Publicado: (2023)

Tocilizumab in severe COVID-19
por: Lucio Liberato, Nicola, et al.
Publicado: (2020)

What's New in Critical Illness and Injury Science? Mortality effects of tocilizumab for patients admitted with COVID-19 pneumonia
por: Miller, Andrew C., et al.
Publicado: (2021)

Benchmarking tocilizumab use for giant cell arteritis
por: Conway, Richard, et al.
Publicado: (2022)

Timely administration of tocilizumab improves outcome of hospitalized COVID-19 patients
por: Rutgers, Abraham, et al.
Publicado: (2022)

Hyper-inflammatory Syndrome in a Child With COVID-19 Treated Successfully With Intravenous Immunoglobulin and Tocilizumab
por: Balasubramanian, S., et al.
Publicado: (2020)

Tocilizumab for hospitalized patients with COVID-19
por: Afra, Kevin, et al.
Publicado: (2021)

Thromboinflammation response to tocilizumab in COVID‐19
por: Gergi, Mansour, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Mourad, Jean-Jacques, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Lipworth, Brian J, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Piano, Salvatore, et al.
Publicado: (2020)

Causal Bayesian machine learning to assess treatment effect heterogeneity by dexamethasone dose for patients with COVID-19 and severe hypoxemia
por: Blette, Bryan S., et al.
Publicado: (2023)

Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients
por: Sarhan, Rania M., et al.
Publicado: (2022)

Administration Timing and Efficacy of Tocilizumab in Patients With COVID-19 and Elevated IL-6
por: Li, Pan, et al.
Publicado: (2021)

Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome
por: Sarhan, Neven Mohamed, et al.
Publicado: (2023)

Candidemia in COVID‐19 treated with corticosteroids and tocilizumab
por: Yamamoto, Koichiro, et al.
Publicado: (2021)

Tocilizumab in COVID-19: enthusiasm vs. evidence
por: Zeña-Huancas, Paola, et al.
Publicado: (2021)

Tocilizumab in COVID-19: The Cerrahpaşa-PREDICT score
por: Eşkazan, Ahmet Emre, et al.
Publicado: (2021)

Tocilizumab is recommended for the treatment of severe COVID-19
por: Zhou, Yonggang, et al.
Publicado: (2020)

Tocilizumab and liver injury in patients with COVID-19
por: Serviddio, Gaetano, et al.
Publicado: (2020)

Tocilizumab, Adipokines and Severe Complications of COVID-19
por: Fioravanti, Antonella, et al.
Publicado: (2020)

Appropriate use of tocilizumab in COVID-19 infection
por: Keske, Şiran, et al.
Publicado: (2020)

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
por: Stone, John H., et al.
Publicado: (2020)

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
por: Salama, Carlos, et al.
Publicado: (2020)

Efficacy and safety of tocilizumab in COVID-19 patients
por: Zheng, Kai-Lian, et al.
Publicado: (2020)

Neues zu Tocilizumab bei COVID-19
por: Borchers, Moritz
Publicado: (2022)

TOCILIZUMAB IN COVID-19: EAST-AFRICAN EXPERIENCE
por: SHAH, R., et al.
Publicado: (2022)

Editorial: Tocilizumab, a Humanized Therapeutic IL-6 Receptor (IL-6R) Monoclonal Antibody, and Future Combination Therapies for Severe COVID-19
por: Parums, Dinah V.
Publicado: (2021)

553. Critically Ill patients Receiving Tocilizumab Compared With Those Not Receiving Tocilizumab for Treatment of COVID-19
por: Leonard, Michael, et al.
Publicado: (2020)

Tocilizumab Outcomes in Critically Ill COVID-19 Patients Admitted to the ICU and the Role of Non-Tocilizumab COVID-19-Specific Medical Therapeutics
por: Elhazmi, Alyaa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_82c6t7v7tbokikpdo27hutr11u